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Abstract
Chorea can be caused by a multitude of etiologies: neurodegenerative, pharmacological, structural, metabolic, and others. In absence of other apparent causes,
exclusion of Huntington’s disease is often a first step in the diagnostic process. There are a number of neurodegenerative disorders whose genetic etiology has been
identified in the past decade. Molecular diagnosis has enabled genetic identification of disorder subtypes which were previously grouped together, such as the
neurodegeneration with brain iron accumulation disorders and the neuroacanthocytosis syndromes, as well as identification of phenotypic outliers for recognized
disorders. Correct molecular diagnosis is essential for genetic counseling and, hopefully, ultimately genetic therapies. In addition, there has recently been recognition
of other disorders which can mimic neurodegenerative disorders, including paraneoplastic and prion disorders. This article focuses upon recent developments in the
field but is not intended to provide an exhaustive review of all causes of chorea, which is available elsewhere. I also discuss the nomenclature of these disorders which
has become somewhat unwieldy, but may ultimately be refined by association with the causative gene.
Keywords: Chorea, neurodegeneration with brain iron accumulation, neuroacanthocytosis
Citation: Walker R. Update on the non-Huntington’s disease choreas with comments on the current nomenclature. Tremor Other Hyperkinet Mov 2012;2:
http://tremorjournal.org/article/view/49
* To whom correspondence should be addressed. E-mail: ruth.walker@mssm.edu
Editor: Elan D. Louis, Columbia UniversityUnited States of America
Received: June 29, 2011 Accepted: August 8, 2011 Published: January 30, 2012
Copyright: ’ 2012 Walker. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the
user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not altered or
transformed.
Funding: None.
Competing Interests: The author reports no conflict of interest.
Introduction
Chorea can be caused by a multitude of etiologies: neurodegenera-
tive, pharmacological, structural, metabolic, and others. This article
focuses upon recent developments in the field. I also discuss the
nomenclature of these disorders, which has become somewhat
unwieldy, but may ultimately be refined by association with the
causative gene. This article is not intended to provide an exhaustive
review of all causes of chorea, as this is available elsewhere.1,2
The identification in 1993 of the causative trinucleotide repeat
expansion within the gene responsible for Huntington’s disease (HD)3
was the starting point for the recognition that there were other genetic
causes of chorea. Prior to this, any patient with a progressive
movement disorder and neuropsychiatric changes was given the
diagnosis of HD, particularly if there was a positive family history.
However, between 1%4 and 12–15%5,6 of patients thought to have
HD were found to be negative for the HD mutation. The identification
of the HD gene led to the search for other genes that could cause
familial basal ganglia neurodegenerative syndromes. In addition, it
became possible to make the diagnosis of HD in those with atypical
features, such as late age of onset and the absence of a family history,
who had previously been given the now-obsolete label of ‘‘senile
chorea.’’
‘‘Huntington’s disease-like’’ disorders
The grammatically clumsy naming, involving an adjectival construct
masquerading as a noun, of the Huntington’s disease-like (HDL)
disorders, commenced in 1998 with HDL1.7 Although traditional
requirements for being ‘‘HDL’’ should have been autosomal dominant
(AD) inheritance, in addition to comprising a progressive hyperkinetic
movement disorder and cognitive impairment, one of the four
disorders with this unfortunate name demonstrated autosomal
recessive inheritance (HDL3).
The term HDL1 was used to describe a family with a disorder
characterized by personality changes starting in early–mid adulthood,
followed by chorea, rigidity, dysarthria, myoclonus, and ataxia, and
seizures.7 Symptoms developed in three generations, demonstrating
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AD inheritance. This disease was determined to be a prion disorder
due to an octapeptide repeat.8 Other families with this mutation have a
different phenotype in which psychiatric features predominated over a
variety of cerebellar, pyramidal or parkinsonian signs.9
HDL2 was reported initially as being due to a CAG repeat
expansion, with AD inheritance and clinical features very similar to
HD, in one family.10 The mutation was subsequently identified as
being a CTG/CAG trinucleotide repeat expansion located within a
variably spliced exon, labeled 2A, between exon 1 and exon 2B of
junctophilin-3 (JPH3) on chromosome 16q24.3.11 Unusually, neurode-
generation appears to be due to transcription of the antisense CAG
repeat.12 In addition, mRNA toxicity, in common with myotonic
dystrophy 1 and some of the spinocerebellar ataxias (SCAs),13 may
play a significant role in pathogenesis.12 Intriguingly, the latter feature
may be shared with HD, and may offer insights into a common disease
mechanism.
Only reported to date in subjects of black African ancestry,
HDL2 has been found in many countries,5,10,11,14–16 especially among
black South Africans. Ten percent may have acanthocytes, resulting in
the inclusion of this disorder with neuroacanthocytosis syndromes.17
The term HDL3 was given to five affected siblings with chorea,
dystonia, dysarthria, cognitive impairment, and seizures.18
Neuroimaging showed cortical and caudate nucleus atrophy.
Although linkage localized the mutation to the vicinity of the HD
gene, HD was excluded. No further cases have been reported with this
disorder, nor has a causative gene been identified.
HDL4 was the term given to what transpired to be a familial
phenotypic variation of SCA17:19 1% of a cohort of non-HD patients
were found to have this mutation.5 Although ataxia is a more typical
presentation of SCA17, in some families there may be striking
phenotypic homogeneity.20
Fortunately, no new disorders have been given an ‘‘HDL’’ name. In
addition to being inelegant, the absence of the noun in the term, which
most logically would be the repetitive ‘‘disease’’ (‘‘Huntington’s
disease-like disease 2’’), makes the name challenging to translate into
other languages such as French or German, where the ending of the
adjective should agree with the gender of the noun.
It is this author’s hope that this terminology will be abandoned and
the named HDL disorders given names related to their causative
mutation. One option would be to follow the convention of the
neurodegeneration with brain iron accumulation (NBIA) disorders,
e.g. ‘‘junctophilin 3-associated neurodegeneration (J3AN).’’ Another
alternative would be to adopt terminology similar to that for the
neurodegenerative disorders characterized by abnormal protein
accumulation, such as ‘‘tau-opathy’’ and ‘‘synuclein-opathy,’’ hence
‘‘junctophilin-opathy.’’ One distinction from these disorders is that in
general this terminology has been used to refer to accumulation of the
specified protein on neuropathological examination, rather than the
causative mutation. Although neither of these options is much more
elegant than ‘‘HDL,’’ it is appealing to use nomenclature which is
etiologically accurate, and has the additional advantage of not being
dependent upon the clinical phenotype which may not be choreiform.
Other trinucleotide repeat disorders
In addition to HDL2 and SCA17, movement disorders can be seen
in some of the other SCAs and dentatorubropallidoluysian atrophy
(DRPLA). In some cases the typical cerebellar findings, such as
abnormalities of eye movement and ataxia, are less prominent than the
movement disorder. Parkinsonism, dystonia, and chorea are not
infrequent in SCA3 (Machado–Joseph disease), the most common
SCA in most populations. Patients with SCA121 and SCA222,23 may
occasionally present with or develop chorea. There does not seem to
be a relationship between size of the trinucleotide repeat expansion
and the phenotype.
DRPLA was initially thought to be seen only in Japanese
populations, but has occasionally been reported in Caucasian24,25 or
African-American26 families. There are two typical phenotypes related
to the age of onset, and thus in this case correlate with the size of the
trinucleotide repeat expansion. In younger onset patients myoclonus
and seizures are prominent, in addition to ataxia and dementia. In
patients with age of onset older than 20 years, chorea and
neuropsychiatric symptoms are typical, similar to HD.
Neuroacanthocytosis syndromes
The past decade has seen clarification of the clinically and
genetically heterogeneous disorders given the term ‘‘neuroacanthocy-
tosis.’’ This term is still often used to refer to cases for which the more
accurate term, especially if genetic or protein confirmation has been
performed, is chorea-acanthocytosis (ChAc; also referred to as
choreoacanthocytosis).
Following the seminal reports by Levine et al.,27 and Critchley
et al.,28 in the 1960s, of a neurological disorder accompanied by
acanthocytes with normal lipoproteins, the term ‘‘neuroacanthocyto-
sis’’ was adopted, despite the potential for confusion with the disorders
of lipoproteins (abetalipoproteinemia [Bassen–Kornzweig disease] and
hypobetalipoproteinemia). The term ‘‘Levine–Critchley’’ syndrome
was used initially by authors from Japan, where ChAc is more
common.29 The widely cited case series published by Hardie et al. in
199130 unfortunately perpetuated diagnostic confusion due to its
genetic heterogeneity, but has subsequently been updated.31 It has
recently been confirmed that Critchley’s original Kentucky kindred
were indeed affected by ChAc.32
The identification of mutations in VPS13A (encoding for vacuolar
protein sorting-associated protein 13A) as the cause, and the affected
protein as chorein,33–35 has facilitated precise diagnosis of ChAc.36 Use
of Western blotting to demonstrate absence of the protein has been
useful in clinical practice.37 Molecular conformation is challenging due
to the large gene size and the many locations and natures of
mutations,38 but may be made easier with recent advances in genetic
techniques.
As both acanthocytes39–41 and chorea may be variable or absent at
any point in a patient’s clinical course, it has been suggested that the
name ‘‘chorea-acanthocytosis’’ is inaccurate. As the affected protein
has been named ‘‘chorein,’’ a more appropriate term may be ‘‘chorein
disease,’’ ‘‘chorein-associated neurodegeneration,’’ or ‘‘chorein-opathy,’’
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although I am reluctant to advocate for yet another change in
nomenclature for a disorder whose taxonomy has already resulted in
confusion.
Recognition of an association of the McLeod blood type42,43 with
various movement disorders, including chorea, parkinsonism, tics,
and dystonia, has permitted molecular diagnosis of this X-linked
neuroacanthocytosis syndrome (McLeod syndrome; MLS).44–46
Although very rare, with fewer than a hundred published cases,47
this diagnosis is important because of the potential complications
of blood transfusion incompatibility and preventable cardiac
complications.44,48
Potential diagnostic confusion may be caused by the observations of
acanthocytes in HDL217 and in pantothenate kinase-associated
neurodegeneration (PKAN).49 Indeed, one of Hardie’s original series
was likely to have had this disorder (initially given the name
hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa and
pallidal degeneration [HARP]50).
The mechanism for the production of acanthocytes is not known. In
PKAN, it is likely that this is a result of impaired lipid synthesis;
however, this hypothesis raises the question as to why acanthocytosis is
not a universal finding in these patients.
Neurodegeneration with brain iron accumulation
This group of disorders is characterized by the finding on magnetic
resonance imaging (MRI) of iron deposition primarily in the globus
pallidus. Prior to the advent of MRI, the diagnosis was made only post
mortem, on the basis of neuropathological findings. The disorders
were described as ‘‘Hallervorden–Spatz disease’’ or ‘‘Hallervorden–
Spatz syndrome’’ if atypical. Causative mutations in the PANK2 gene
were discovered,51 and the term ‘‘pantothenate kinase-associated
neurodegeneration’’ was proposed in light of the unethical nature of
the work of Drs. Hallervorden and Spatz in Nazi Germany.52,53 The
prototypical NBIA disorder, PKAN, typically presents in childhood
with dystonia, rather than chorea, in addition to other findings such as
pigmentary retinal degeneration.49 The disorder initially termed
HARP was found to be allelic with PKAN.50,54
Adult onset of basal ganglia iron deposition is associated with
chorea. A small number of families have been reported with autosomal
dominant inheritance of mutations of ferritin light chain, responsible
for iron transportation, resulting in neuroferritinopathy.55–58
Autosomal recessive inheritance of mutations of ceruloplasmin,59,60 a
ferroxidase, results in chorea and dystonia, often orofacial, with the
addition of ataxia. Symptomatic heteroplasmic carriers have been
reported.61 The pattern of basal ganglia iron deposition can be
distinguished in the different disorders by distinctive patterns of iron
and inflammation on neuroimaging.62
Childhood-onset NBIA disorders appear to be characterized by
dystonia and parkinsonism, and include one phenotype of neuroaxonal
dystrophy, due to mutations of PLA2G6 (phospholipase-associated
neurodegeneration; PLAN),63–65 Kufor–Rakeb syndrome (PARK9;
ATP13A2 mutations),66 and fatty acid hydroxylase-associated neuro-
degeneration (FAHN),67 and a growing list of other disorders.
Benign hereditary chorea
Benign hereditary chorea is so called as it does not appear to be
associated with a dementing process or severe neurological impair-
ment. It has been associated with mutation of thyroid transcription
factor 1 (TITF-1),68–70 also known as NKX2.1. However, this mutation
is not found in all families, and the disorder appears to be genetically71
and possibly phenotypically72 heterogeneous. Onset may be in
childhood, and there is sometimes also mild ataxia. The chorea may
respond to l-dopa.73 Neuropathological findings are subtle and reflect
alterations in a subset of striatal interneurons.74 Subtle changes are
reported on structural and functional neuroimaging.75,76
Mutations of the same gene have been reported to cause a
multisystem disorder comprising congenital hypothyroidism, hypoto-
nia, and pulmonary problems, in addition to chorea.70,77–79
Differences in the size and nature of mutations may account for the
varying severity in these two disorders.
Autoimmune disorders
An expanding number of paraneoplastic neurologic syndromes have
been recognized. Although much less common than cerebellar and
neuromuscular presentations, chorea has been reported in renal, small
cell lung, breast, Hodgkin’s and non-Hodgkin’s lymphoma,80–84 due to
anti-CRMP-5/CV283,85 or, occasionally, anti-Hu84 or anti-Yo86
neuronal autoantibodies.
Although not technically choreiform in nature, the identification
of the anti-N-methyl-D-aspartate (NMDA)-receptor antibody-related
syndrome is mentioned here due to its apparent frequency and recent
insights into its course and pathogenesis.87–91 This disorder results in
encephalopathy with complex, often stereotypic movements with
components of dystonia and chorea. In some patients ovarian
teratomas are identified, although in others the etiology remains
obscure.87 Importantly, some patients may recover after a prolonged
disease course.
Prion diseases
Prion disease both inherited and sporadic may cause chorea,92
rather than the more typical movement disorder presentation of
myoclonus in a patient with progressive cognitive deterioration. In
addition to HDL18 (discussed above), new variant Creutzfeldt–Jakob
disease, related to bovine spongiform encephalopathy, can cause
chorea and cognitive impairment which progress subacutely over
months.93,94
Advances in therapies
Neurosurgical advances for other movement disorders appear to
have benefited patients with the non-HD choreas, although at present
it is challenging to accurately gauge success rates as cases with poor
outcomes are less likely to be reported. There is a need to collate all
cases receiving surgery for each of these rare diseases in order to
provide general recommendations.
Case reports and small series have reported the effects of deep brain
stimulation (DBS) or lesioning of the subthalamic nucleus (STN) or
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globus palldus pars interna (GPi) in patients with chorea of various
etiologies. Case reports of DBS of the GPi in ‘‘senile chorea’’95 have
been promising, although in ChAc96–98 and MLS99 results are mixed.
The benefits in these progressive disorders may be limited by ongoing
neurodegeneration. The motor thalamus has also been proposed as a
potentially promising site for DBS in ‘‘senile chorea’’95 and has been
reported as being beneficial in a patient with ChAc.96,99 The optimal
site and frequency of stimulation for treatment of chorea remain to be
identified.99 Positive results following pallidotomy have been reported
in DRPLA100 and ChAc.101
The most significant advance in medical therapies in the USA has
been the recent approval of tetrabenazine,102,103 which depletes
monoamines from presynaptic terminals.104 However, the side effects
of depression, parkinsonism, and impaired swallowing may be
limiting,105 and tetrabenazine should be used with care. Reserpine
may also be useful with the same caveats.
As in HD, the newer atypical antipsychotics, including clozapine,
quetiapine, aripiprazole, and ziprasidone have been a useful addition
to the pharmacological armamentarium. Although parkinsonism and
tardive dyskinesia can occasionally be seen with these agents, and
sedation can be a significant problem, weight gain is rarely an issue in
patients with neurodegenerative choreas, and thus these medications
can be helpful.
Other agents with different mechanisms of action have been
reported to give benefit in non-HD choreas, including levetirace-
tam,106 possibly related to a membrane-stabilizing effect. However,
caution should be employed, as some anticonvulsants, such as
lamotrigine, have been reported to worsen involuntary movements
in ChAc.107 Glutamatergic NMDA-receptor antagonists such as
amantadine and riluzole may reduce chorea in HD108–112 and may
be considered in non-HD choreas.
Neuroimaging
Although limited by the rarity and clinical heterogeneity of these
disorders, quantitative neuroimaging has resulted in demonstration of
specific features in some of the non-HD choreas, such as specific
atrophy affecting the head of caudate nucleus in ChAc113–115 and
progression of neurodegeneration in MLS44,116
Studies of metabolism such as magnetic resonance spectroscopy are
in their infancy, but may ultimately lead to additional insights into
disease pathogenesis.117
Future needs
Despite recent advances with progress in molecular medicine, a
significant number of subjects with chorea remains undiagnosed. The
rarity of many of these disorders means that funding for research is
limited, especially in the current climate. There is a need for an
internationally accessible database of clinical descriptions, neuroimag-
ing findings, other laboratory features, and tissue samples for all non-
diagnosed subjects with chorea, with or without family history. This
could be modeled upon the neuroacanthocytosis database (http://
www.euro-hd.net/html/na/submodule/), which has been piggy-backed
onto the European Huntington’s disease database (http://euro-hd.
net), with the addition of a centralized tissue bank. Such a resource
could be used, for example, for genetic studies, for screening for
serological and neuroimaging biomarkers, for searches for distin-
guishing phenotypic features, and would be a rewarding use of the
technology now at our disposal.
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